Previous 10 | Next 10 |
Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and related conditions, has signed a non-binding term sheet (the “Term Sheet”) with Tel...
QSAM Biosciences (OTCQB: QSAM) , a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of bone cancer and related diseases, today issued a letter to its shareholders. In the letter, the company’s...
AUSTIN, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam ® ), for the treatment of bone cancer and related diseases, today issued the followi...
QSAM Biosciences (OTCQB: QSAM) is a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals for the treatment of cancer and other diseases and conditions. The company today announced the qualification and addition of the nuclear reactor at the University ...
Austin, TX, June 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals for the treatment of cancer and other diseases and conditions, announced today the qualification and addi...
QSAM Biosciences (OTCQB: QSAM) , a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, has added a site for its phase 1 study. The company ann...
Austin, TX, May 23, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam ® ), for the treatment of bone cancer and other diseases and conditions, today announces the...
QSAM Biosciences (OTCQB: QSAM) , a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, has announced a partnership with RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the country. The two companies have a commercial s...
Partnership is Latest in Series of RLS Effort s to Expand Industry-Leading CDMO Business and Clinical Trial Capability with Radiopharmaceutical Partners Across U.S. Austin, TX and Lake Zurich, IL, May 16, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc...
2023-04-26 08:56:34 ET QSAM Biosciences ( OTCQB:QSAM ) announced the reception of a second patent from the European Patent Office. The patent safeguards the use of "lower specific activity" Samarium-153 when treating bone cancer in children and adults. This new patent in Europe co...
News, Short Squeeze, Breakout and More Instantly...
QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company a...
Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc . (OTCQB: QSAM) (“ QSAM ” or the “ Company ”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par...
QSAM Biosciences (OTCQB: QSAM) , a clinical-stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, has signed a definitive agreement and plan of merger pr...